Midatech Pharma Plc (LON:MTPH) target maintained at 380.00GBX, issued a ratings update earlier today by Panmure Gordon
- Updated: September 29, 2016
Yesterday Midatech Pharma Plc (LON:MTPH) traded 8.53% higher at 131.50GBX. The company’s 50-day moving average is 144.99GBX and its 200-day moving average is 141.70GBX. The last stock close price is down -6.17% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 10,337 shares of MTPH traded hands, down from an avg. volume of 21,248
Indicating a possible upside of 1.89%, Panmure Gordon hold steady the target of Midatech Pharma Plc (LON:MTPH) at 380.00GBX
Previously on 09/21/2016, Panmure Gordon reported about Midatech Pharma Plc (LON:MTPH) held steady the target price at 380.00GBX. At the time, this indicated a possible upside of 1.58%.
See Chart Below
Midatech Pharma Plc has a 52 week low of 100.51GBX and a 52 week high of 285.00GBX The company’s market cap is currently 0 GBX.
In addition to Panmure Gordon reporting its target price, a total of 2 brokers have issued a report on MTPH. The one year target is 388.00GBX with 0 firms rating the company a strong buy, two analysts rating the stock a buy, 0 brokerages rating the company a hold, zero firms rating the stock a underperform, and finally zero equity analysts rating the company a sell.
More About Midatech Pharma Plc (LON:MTPH)
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.